Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium.
Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
J Viral Hepat. 2021 Jan;28(1):105-111. doi: 10.1111/jvh.13414. Epub 2020 Oct 14.
Hepatitis B virus (HBV) immunity is recommended to optimize outcomes after solid organ transplantation (SOT). This study assessed the prevalence and predictors of HBV immunity at the time patients were placed on transplant waiting list over a period from 1997 to 2019 in a low HBV endemic region.
Data were obtained from the University Hospitals Leuven transplant database. Minors and patients with past/current HBV infection were excluded. From 1986, Belgian patients are covered by the universal infant vaccination; therefore, birth cohort was stratified in those born ≥1986 vs <1986.
The study population consisted of 3297 SOT candidates. HBV immunity rate was superior in renal transplant candidates (55.3%), and this number was 21.5%, 15.4% and 16.8% for liver, cardiac and pulmonary transplant candidates, respectively, P < .001. Among liver transplant candidates, HBV immunity rate was 14.8% in decompensated cirrhotic patients and 27.9% in those without advanced cirrhosis (P < .001). The overall immunity rate increased from 19.3% in period 1997-2008 to 32.8% in 2009-2019, P < .001. In multivariable analyses, younger age (odds ratio (OR) 95% confidence interval (CI): 0.97-0.98, P < .001) and birth cohort ≥ 1986 (OR 95% CI: 1.18-2.66, P = .006) were associated with increased HBV immunity.
An increase in HBV immunity was observed over a 20-year period related to the introduction of universal infant HBV vaccination. Nevertheless, this study highlights the low overall HBV immunity at the time of listing for organ transplantation and points out the need of an increased awareness and vaccination strategy at an early disease stage.
乙型肝炎病毒 (HBV) 免疫被推荐用于优化实体器官移植 (SOT) 后的结果。本研究评估了在低 HBV 流行地区,1997 年至 2019 年期间患者在等待移植名单期间 HBV 免疫的流行率和预测因素。
数据来自鲁汶大学医院移植数据库。排除未成年人和有既往/现症 HBV 感染的患者。自 1986 年以来,比利时患者普遍接受婴儿疫苗接种;因此,按出生队列分为 1986 年及以后出生和 1986 年以前出生。
研究人群包括 3297 名 SOT 候选者。肾移植候选者的 HBV 免疫率较高(55.3%),而肝、心和肺移植候选者的这一数字分别为 21.5%、15.4%和 16.8%,P<0.001。在肝移植候选者中,失代偿性肝硬化患者的 HBV 免疫率为 14.8%,无晚期肝硬化患者的 HBV 免疫率为 27.9%(P<0.001)。总体免疫率从 1997-2008 年的 19.3%增加到 2009-2019 年的 32.8%,P<0.001。多变量分析显示,年龄较小(优势比[OR]95%置信区间[CI]:0.97-0.98,P<0.001)和出生队列≥1986 年(OR 95%CI:1.18-2.66,P=0.006)与 HBV 免疫增加相关。
在 20 年期间,由于普遍婴儿 HBV 疫苗接种的引入,HBV 免疫率有所增加。然而,本研究强调了器官移植名单上列出时总体 HBV 免疫率较低,并指出需要在疾病早期提高认识和疫苗接种策略。